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Abstract: The recently discovered JAK2 V617F point mutation, found in 50–60% of ET patients, has been
reported to be associated with a higher risk of thrombotic events. In this study, we explored if JAK2 V617F
mutation, or coexisting thrombophilic and hemostatic risk factors, contributed to these complications. We ex-
amined 32 patients with ET, and looked for pathogenetic JAK2 V617F mutation and prothrombotic genes mu-
tations: factor V Leiden, prothrombin and MTHFR. We also evaluated plasma levels of fibrinogen, factors VIII
and XII, AT, protein C, protein S and serum level of homocysteine. Urokinase concentration was assessed in
patients’ plasma as well as platelet lysates. There was no difference in the number of thrombotic complications
between ET patients with and without JAK2 mutation. However, we found a number of thrombophilic and
hemostatic risk factors that could contribute to thrombotic complications in ET patients. (Folia Histochemica et
Cytobiologica 2011; Vol. 49, No. 2, pp. 267–271)
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Introduction
The recently discovered tyrosine-kinase activating
JAK2 V617F point mutation is found in 50–60% of
essential thrombocythemia (ET) patients. An in-
creased risk of thrombosis in patients with this muta-
tion, especially the homozygous type, has been report-
ed. Other factors which can increase the risk of throm-
bosis arising from ET itself are: hereditary thrombo-
philic factors like antithrombin, protein C and protein
S deficiency, the mutation of the prothrombin gene,
the Leiden mutation of factor V gene, the MTHFR
gene mutation, decreased FXII level, hyperhomocys-
teinemia, as well as increased levels of some coagula-
tion factors such as FVIII, vWF, and fibrinogen.
In this study, we explored whether the JAK2
V617F mutation or coexisting thrombophilic and he-
mostatic risk factors contribute to thrombotic com-
plications in ET patients.
Material and methods
We examined 32 patients with ET (24 females, eight males,
mean age 56.0 ± 14.2 years). The 32 comprised ten untreated
patients, ten treated with anagrelide, nine with hydroxyurea
and three treated with both drugs. The control group (CG)
consisted of 20 healthy volunteers (14 females, six males,
mean age 41.4 ± 8.3). We searched for pathogenetic JAK2
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V617F mutation and prothrombotic factors such as: Factor
V Leiden, prothrombin gene and MTHFR gene mutations.
We also evaluated plasma levels of fibrinogen, factor VIII,
factor XII and AT using coagulometric methods (reagents
from Dade Behring) and protein C and free protein S using
coagulometric methods (reagents from HemosILTM). Uroki-
nase concentration was assessed in plasma and in platelet
lysates using ELISA (IMUBIND uPA kit from American
Diagnostica Inc.). Homocysteine level was evaluated using
the immunoenzymatic method (kit from DPC). Platelet ac-
tivation was studied using monoclonal mouse anti-human:
CD42b/RPE,CD61/FITC,CD62P/RPE antibodies from
Dako and flow cytometry to detect CD61/CD42b and CD61/
/CD 62P protein expression on the platelet surface.
JAK2 V617F point mutation was detected using allele-
specific-PCR (Roche) [1]. Peripheral blood genomic DNA
was isolated using QIA amp DNA Blood Mini KIT
(QIAGEN). The tetra-primer PCR method was used to
genotype point V617F mutation [2].
To evaluate prothrombotic mutations, blood samples for
deoxyribonucleic acid (DNA) analysis were collected into
tubes containing disodium ethylenediaminetetraacetic acid
(EDTA). DNA was extracted from blood samples by the
salting out procedure devised by Miller et al. [3]. PCR prod-
ucts were screened for Leiden mutation using MnL1 re-
striction enzyme according to Bertina et al. [4]; for prothrom-
bin gene mutation G20210A acc. to Poort et al. [5] using
HindIII restriction enzyme; and for MTHFR C677T acc. to
Frosst et al. [6] using HinfI restriction endonuclease.
Results
Patients’ characteristics
Mean platelet count was 785 ± 32 G/l for ET patients
and 250 ± 54 G/l for the control group. The differ-
ence between both groups was statistically significant
(p < 0.001). White blood cell count (WBC) was also
higher in ET patients than in the control group: 8.3 ±
± 3.7 G/l and 5.4 ± 1.4G /l respectively, p < 0.001.
The concentration of uPA was higher in patient plas-
ma compared to the control group (0.635 ± 0.232 ng/
/ml vs. 0.447 ± 0.115 ng/ml respectively, p < 0.05).
Mean uPA concentration measured in platelet lysates
was similar in both groups (ET 0.317 ± 0.135 ng/109
platelets, CG 0.290 ± 0.065 ng/109 platelets). Median
homocysteine serum level was similar in both groups
(ET 9.77 μmol/l, P 25–75% 8.11–12.4 vs. CG 9.21
μmol/l, P 25–75% 7.94–10.60 μmol/l). In the ET
group, hyperhomocysteinemia was detected in 31%
of patients, and only in two persons simultaneously
with MTHFR gene mutation. In two patients from
this group, the level of homocysteine was extremely
high. One of them, a 76 year-old woman, underwent
heart infarct three times. Her other risk factors were
hypertension and JAK2 mutation. Her homocysteine
level was extremely high (24.6 μmol/l), without
MTHFR gene mutation. Coronarography revealed nor-
mal coronary arteries. The other patient, a 79 year-old
man with a very high homocysteine level (21.7 μmol/l)
had obliterative atheromatosis diagnosed at the same
time as ET. No JAK2 and MTHFR gene mutations
were detected.
In 11 patients from the ET group, 19 MPD-re-
lated thrombotic vascular events occurred (Table 1).
There were ten (50%) arterial thrombosis events
including: ischemic strokes (three events), myocar-
dial infarctions (five events), femoral artery embo-
lism (one event) and obliterative atheromatosis
(one event).
Events involving the venous system were: deep vein
thrombosis (four events), toe vein thrombosis (one
event), superficial phlebitis (two events), stillbirth
(one event) and portal and splenic vein thrombosis
(one event). In the latter case, diagnosed with portal
and splenic vein thrombosis in 1999 when she was 38
years old, ET was only discovered seven years later.
Her platelet count in 1999 was normal. These throm-
botic events were preceded by DVT that occurred prob-
ably because the patient received birth control pills.
Consequently, in 2004 the patient underwent a sple-
nectomy. After the splenectomy, platelet count con-
tinued to increase and in 2006, after bone marrow tre-
phine biopsy, ET was finally diagnosed. This patient
carries a JAK2 V617F mutation which was diagnosed
in 2007, but at the time of the occurrence of portal and
splenic vein thrombosis we had no way of evaluating
it. Other thrombotic risk factors which still exist in this
patient are hypercholesterolemia and a high level of
antinuclear antibodies. Only in 2010 was a homozy-
gous genotype of MTHFR T/T determined with nor-
mal homocysteine level.
Thrombotic complications were noticed in two
persons in the control group (Table 1).
Table 1. Specification of thrombotic complications
Group Thrombotic complication (number) Thrombotic complication — specification
ET 11 Stillbirth (1), DVT (1), portal vein thrombosis (1), heart infarct (2), superficial
(6 with and 5 without JAK mutation)  thrombophlebitis (1), cerebro-vascular event (2), cerebrovascular event + DVT (1),
great toe vein thrombosis (1), peripheral arterial disease (1)
Control 2 DVT after delivery (1), minor cerebrovascular event (1)
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Bleeding episodes were noticed in seven ET pa-
tients (Table 2). In two patients these episodes (alve-
olar hemorrhage and gastrointestinal bleeding) oc-
curred when the platelet count was very high (in the
first patient 2,300 G/l, in the second 1,100 G/l). Be-
cause of these clinical manifestations, ET was diag-
nosed. In three previously diagnosed patients, hem-
orrhages after trauma were observed and the platelet
count was below 1,000 G/l. In the last two patients,
hypermenorrhoea was observed long before the di-
agnosis of ET was made, but at that time platelet count
exceeded the normal limit.
Patients with thrombotic complications were old-
er than those without any complications (65.9 ± 10.8
vs. 47.7 ± 13.0 years, p < 0.05) and had higher fibrin-
ogen and factor VIII levels (420 mg/dl vs. 302 mg/dl
p < 0.05, and 115% vs. 88%, p < 0.05 respectively).
Patients with thrombotic complications as compared
statistically to those with bleeding episodes were also
significantly older. Additionally, among ET patients
with thrombotic vascular events, six were older than
60 years at the time of the first event. Analyzing the
patients with regard to the relation of vascular event
to the time of diagnosis, we came up with the follow-
ing: four patients underwent vascular event long be-
fore ET diagnosis; in three patients the ET diagnosis
was made as a result of a vascular event; and in four
patients a vascular event occurred after an ET diagno-
sis was made. A statistically significantly lower CD61/
/42b protein expression was detected (1.74% vs. 10.00%,
p < 0.05) in patients with thrombotic complications com-
pared to patients without these complications.
Assessment of point mutations
The JAK2 V617F point mutation was detected in 18
(60%) tested ET patients but not in the control group.
In all cases, the heterozygous genotype was deter-
mined. In 39.3% of ET patients, the MTHFR (MTHFR
C677T) gene mutation was detected. In one ET pa-
tient (3.6%), the homozygous genotype was detect-
ed. This was the person who developed portal and
splenic vein thrombosis. All other patients had the
heterozygous genotype. In six patients, JAK2 V617F
point mutation and MTHFR C677T mutation were
found simultaneously.
In the control group, 13 (65%) persons presented
with MTHFR gene mutation. In one person, the ho-
mozygous genotype (MTHFR T/T) was determined.
This was the person with thrombotic complications
(DVT) after child delivery. All the other 12 (60%) sub-
jects had the heterozygous genotype (MTHFR C/T)
and among them one had had a minor cerebrovascu-
lar event. No prothrombin gene G20210A mutation
was found in either ET patients or the control group.
In two patients, and in two control subjects, heterozy-
gous genotype for Leiden mutation was detected. In
two patients, and in one control subject, heterozygous
genotypes for Leiden and for MTHFR gene mutations
were discovered simultaneously (Table 3).
There was no difference in the number of throm-
botic complications between ET patients with and
without JAK2 mutation. The ET patients with JAK2
point mutation had a higher level of red blood cells
(4.38 ± 0.57 T/l and 3.86 ± 0.55 T/l, p < 0.05 respec-
tively), confirming hypersensitivity of mutated pro-
genitor cells to cytokines like erythropoietin (EPO).
Assessment of coagulation factors
The activity of factor XII in JAK2 positive patients
was lower than in negative ones (83.2 ± 25.5% and
109.0 ± 20.4% respectively, p < 0.05). In ET patients
carrying the MTHFR gene mutation (compared to
Table 3. Summary of mutation status in ET and control groups
Group JAK2 mutation MTHFR mutation G 20210A Leiden Leiden + JAK2 +
mutation  mutation  + MTHFR + MTHFR
mutation   mutation
ET 18 (60%) 10 (37%) Heterozygous 0 2 (7%) 2 (7%) 6 (20%)
(32) Heterozygous 1 (3.6%) Homozygous
Control 0 12 (60%) Heterozygous 0 2 (10%) 1 (5%) 0
(20) 1 (5%) Homozygous
Table 2. Specification of bleeding complications
Group Bleeding complication Bleeding complications — specification
ET 7 Alveolar hemorrhage (1), thigh hematoma after trauma (2), hypermenorrhea
(3 with and 4 without JAK mutation) (2), foot hematoma after trauma (1), gastrointestinal bleeding (1)
Control 0 None
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wild type for MTHFR) a higher level of plasma uroki-
nase was observed (0.747 ± 0.3 ng/l and 0.547 ± 0.2
ng/ml, p < 0.05), which might indicate that the fibrin-
olytic system is partly activated in ET patients, espe-
cially those carrying the MTHFR gene mutation, as
a mechanism compensating for a hypercoagulable
state present in these patients.
Discussion
In 1951, William Dameshek classified polycythemia
vera (PV), essential thrombocythemia (ET) and pri-
mary myelofibrosis (PMF) as pathogenetically relat-
ed myeloproliferative disorders (MPD) [7], since re-
named myeloproliferative neoplasms (MPN). In 2005,
somatic activating mutation in the JAK2 nonrecep-
tor tyrosine kinase (JAK2 V617F point mutation) was
identified in most patients with PV (95%), and in
a significant proportion of patients with ET (50–60%)
and PMF (50–60%) [8]. This gain of function muta-
tion causes hypersensitivity of JAK2 V617F+ cells to
cytokine stimulation [9]. In our study group, the JAK2
V617F point mutation was detected in 60% of ET
patients. Campbell et al. in 2005 suggested that ET
patients expressing JAK2 mutation appear to have
a “PV-like” phenotype [10]. Similarly, in our ET pa-
tients with JAK2 point mutation, a statistically signif-
icantly higher level of red blood cells was found, con-
firming the hypersensitivity of mutated progenitor
cells to cytokines like EPO and “PV-like” phenotype.
Campbell also suggested that ET patients carrying
JAK2 V617F point mutation seem to have an in-
creased incidence of venous thrombosis compared to
JAK2-negative subjects. Among patients with throm-
botic complications, JAK2 mutation was present in
six persons. We did not notice any differences in the
number of thrombotic complications between ET pa-
tients with and without JAK2 mutation. The preva-
lence of intra-abdominal (hepatic, portal and mesen-
teric) vein thrombosis is unusually high among pa-
tients with PV and ET. Splanchnic (portal and he-
patic) vein thromboses have been repeatedly
reported in relatively young female patients and are
often early symptoms which can manifest themselves
long before the correct diagnosis [8]. The same situ-
ation was observed in our young female patient with
portal and splenic vein thrombosis which had oc-
curred seven years before ET was diagnosed. In this
patient, JAK2 V617F mutation and homozygous type
of MTHFR T/T mutation were discovered simulta-
neously, and although the homocysteine level was
normal, the existence of two potentially prothrom-
botic mutations seemed to potentiate the risk of
thrombotic complications. In 2009, Jamrozek-
Jedlińska et al. presented seven patients tested due
to idiopathic portal or splenic vein thrombosis. In
six of them, JAK2 V617F mutation was discovered,
suggesting a myeloproliferative disease as the pri-
mary cause of thrombosis [11]. According to Primig-
nani et al. [12] and Kiladijan et al. [13], all subjects
manifesting a splanchnic vein thrombosis should be
investigated for an occult MPD and searched for the
JAK2 mutation as a matter of routine.
In the PVSG (Polycythema Vera Study Group)
study, the platelet count closest to a thrombotic event
did not predict its occurrence. The same information
was provided by the ECLAP study. Major thrombo-
sis occurred in 8.3% and 9.3% of patients whose base-
line platelet count was greater or lower than 400 G/l,
respectively [14].
Given such findings, it is not surprising that throm-
bocytosis is not considered among the criteria for
thrombosis risk assessment in MPD. In our study
group, most MPD-related thrombotic events (15 out
of 19) occurred when platelet count was greater than
400 G/l. And nine of them occurred before a diagno-
sis of ET had been made. In our opinion, this was
due to the fact that before 2007 we used older diag-
nostic criteria which recommended testing for ET
when the platelet count exceeded 600 G/l. On the
other hand, it has been proved by some investigators
that a high platelet count can contribute to vascular
events only in the microcirculatory system because
the platelet count reduction lowers the risk of micro-
circulatory disturbances [15]. The vast majority of our
patients reported a disappearance of erythromelal-
gia, or a considerable reduction of its intensity, after
decreasing platelet count.
The established risk factors for thrombosis in both
ET and PV are old age (> 60 years) and previous
thrombosis history [16]. We have observed that among
our ET patients, thrombotic complications often oc-
curred at older age and those patients presented more
than one episode.
Among hereditary thrombophilic factors which
can increase the risk of thrombosis are: antithrom-
bin, protein C and protein S deficiency, mutation of
the prothrombin gene and the Leiden mutation of
factor V gene. They are known to have an important
function especially in the pathogenesis of venous
thrombosis. Among our ET patients, protein S defi-
ciency was diagnosed only in one person who, besides
erythromelalgia, presented also one episode of TIA.
The Leiden mutation of factor V was diagnosed in
two ET patients. No clinically significant thrombotic
event occurred in these patients, although one of them
presented infertility. The Italian guidelines for ET
management recommend routine screening only in
ET patients with either a personal or familial history
of thrombosis [17].
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In our opinion, routine screening for thrombophil-
ia in all ET patients might be very useful, especially
done simultaneously with the assessment of other
thrombotic risk factors, because all these factors pre-
sented together can amplify the thrombotic risk aris-
ing from ET itself. To establish the proper role of
thrombophilic factors, it would be necessary to test
a larger group of patients.
In 39.3% of ET patients, and in 60% of persons
from the control group, the MTHFR 677C/T gene
mutation was detected. In one ET patient and in one
person from the control group, the homozygous gen-
otype was discovered and both subjects developed
thrombotic complications. Khandanpour et al. [18]
argued that being homozygous for the MTHFR
C677T allele was associated with an increased risk of
PAD (peripheral arterial disease). A few months lat-
er, McGimpsey et al. [19] stated more precisely that
retinal vein occlusion was caused by elevated total
homocysteine, rather than homozygosity for the
MTHFR C677T genotype. We suppose that not only
a higher homocysteine level, but also a homozygous
mutation of the MTHFR gene, is associated with an
increased risk of thrombotic complications.
Conclusions
1. In the group of patients with a heterozygous
JAK2 point mutation, we have not observed an in-
creased number of thrombotic complications.
2. To evaluate the risk of thrombosis it would be
necessary to assess not only JAK2 mutational status,
but also additional thrombotic risk factors. This is be-
coming increasingly important, because due to new
diagnostic criteria of ET, we can diagnose this disor-
der at a younger age and nowadays the observation
period before cytoreductive treatment is longer. Dur-
ing this observation period, it is possible not only to
detect, but also to actively correct, as many throm-
botic risk factors as possible.
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